Bio-Rad Laboratories, Inc. entered into a definitive agreement to acquire RainDance Technologies, Inc. from Quaker Partners, GE Ventures and others.
January 15, 2017
Share
Bio-Rad Laboratories, Inc. (NYSE:BIO) entered into a definitive agreement to acquire RainDance Technologies, Inc. from Quaker Partners, GE Ventures and others on January 16, 2017. The transaction is expected to close during the first quarter of 2017. Lynda Twomey, Maureen Montgomery, Jeremy Kazzaz, Conner Johnston, Shweta Kumar, Gerald Audant, Elizabeth Gartland, Stephen Gillespie, Michael Shuster, Mark Ostrau, Melanie Mayer, Andrew Kim and Michael Knobler of Fenwick & West LLP acted as legal advisors for Bio-Rad.
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
BIO-RAD LABORATORIES, INC. 
